These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20732648)

  • 1. Treating to re-establish tolerance in inflammatory arthritis - lessons from other diseases.
    Cooles FA; Isaacs JD
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):497-511. PubMed ID: 20732648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological tolerance in the therapy of rheumatoid arthritis.
    van de Ven A; Prakken B; Albani S
    Discov Med; 2007 Feb; 7(37):46-50. PubMed ID: 17343805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral toleragens in rheumatoid arthritis.
    Choy EH
    Curr Opin Investig Drugs; 2000 Sep; 1(1):58-62. PubMed ID: 11249596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
    Kavousanaki M; Makrigiannakis A; Boumpas D; Verginis P
    Arthritis Rheum; 2010 Jan; 62(1):53-63. PubMed ID: 20039433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis.
    Pavletic SZ; Klassen LW; Pope R; O'Dell JR; Traynor AE; Haire CE; Graziano F; Oyama Y; Barr W; Burt RK
    J Rheumatol Suppl; 2001 Oct; 64():28-31. PubMed ID: 11642500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The type I IFN system in rheumatoid arthritis.
    Conigliaro P; Perricone C; Benson RA; Garside P; Brewer JM; Perricone R; Valesini G
    Autoimmunity; 2010 Apr; 43(3):220-5. PubMed ID: 20166872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose immunosuppressive therapy for rheumatoid arthritis: some answers, more questions.
    McSweeney PA; Furst DE; West SG
    Arthritis Rheum; 1999 Nov; 42(11):2269-74. PubMed ID: 10555019
    [No Abstract]   [Full Text] [Related]  

  • 8. Transplantation: tolerance.
    Hutchings A; Thomas JM
    Curr Opin Investig Drugs; 2003 May; 4(5):530-5. PubMed ID: 12833645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease in rheumatoid arthritis: a step forward.
    Myasoedova E; Gabriel SE
    Curr Opin Rheumatol; 2010 May; 22(3):342-7. PubMed ID: 20164773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating autoimmune diseases through restoration of antigen-specific immune tolerance.
    Wolfraim LA
    Arch Immunol Ther Exp (Warsz); 2006; 54(1):1-13. PubMed ID: 16642252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.
    González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
    Arthritis Rheum; 2009 Apr; 60(4):1006-19. PubMed ID: 19333946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.
    Choy E; Sattar N
    Ann Rheum Dis; 2009 Apr; 68(4):460-9. PubMed ID: 19286905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for cytokine and product manipulation to improve the results of autologous stem cell transplantation for rheumatoid arthritis.
    Talmadge JE; Singh R; Ageitos A; Buyukberber S
    J Rheumatol Suppl; 2001 Oct; 64():32-8. PubMed ID: 11642502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutics in rheumatoid arthritis.
    Savage C; St Clair EW
    Rheum Dis Clin North Am; 2006 Feb; 32(1):57-74, viii. PubMed ID: 16504821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune system and new therapies for inflammatory joint disease.
    Oliver SM
    Musculoskeletal Care; 2003 Mar; 1(1):44-57. PubMed ID: 20217663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine networks--towards new therapies for rheumatoid arthritis.
    McInnes IB; Liew FY
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):31-9. PubMed ID: 16932625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
    Gerlag DM; Tak PP
    Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting IL-17 and Th17 cells in rheumatoid arthritis.
    Sarkar S; Fox DA
    Rheum Dis Clin North Am; 2010 May; 36(2):345-66. PubMed ID: 20510238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can proliferation signal inhibitor-induced Tregs really reflect transplantation tolerance in clinical solid organ transplantation?
    Li S; Kuang A; Huang R
    Int Rev Immunol; 2009; 28(5):367-75. PubMed ID: 19811315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.